Ngm Biopharmaceuticals Inc
The NGM stock trades on Nasdaq All Markets
Company Description
At NGM, innovation is perpetual. Our discovery engine is continually exploring potential new research programs, and our journey to the next great discovery is always underway. We are advancing a broad and diverse pipeline of innovative biologic therapeutic candidates — all generated by our in-house discovery engine — based on our scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. We are a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.
We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move biologic drug candidates rapidly into proof-of-concept clinical studies.
We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move biologic drug candidates rapidly into proof-of-concept clinical studies.
Drug Pipeline
Source: Ngm Biopharmaceuticals Inc - 20220930
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
Aldafermin
Liver Diseases
Phase 2
MK-3655
Liver Diseases
Phase 2
NGM120
Cachexia
Phase 1
Cancer
Phase 1
Metastatic Pancreatic Cancer
Phase 2
NGM438
Solid Tumors
Phase 1
NGM621
Geographic Atrophy
Phase 2
0 Comments on NGM stock
Newest
Conversation